CERo Therapeutics Holdings Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • CERO

Stock Symbol

  • Investments
  • 1

CERo Therapeutics Holdings General Information

Description

CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Contact Information

Website
www.cero.bio
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 201 Haskins Way
  • Suite 230
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 201 Haskins Way
  • Suite 230
  • South San Francisco, CA 94080
  • United States
+1 (650)

CERo Therapeutics Holdings Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CERo Therapeutics Holdings Stock Performance

As of 16-Nov-2026, CERo Therapeutics Holdings’s current market cap is $344K with 71.6M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$344K 71.6M 583K $40.34

CERo Therapeutics Holdings Financials Summary

As of 30-Jun-2026, CERo Therapeutics Holdings has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 7,455 9,020
Revenue 0 0 0 0
EBITDA (14,353) (18,846) (6,311) (10,898)
Net Income (16,312) (19,920) (7,290) (11,829)
Total Assets 1,900 3,641 5,126 11,349
Total Debt 965 699 2,944 3,017
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CERo Therapeutics Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CERo Therapeutics Holdings‘s full profile, request access.

Request a free trial

CERo Therapeutics Holdings Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore CERo Therapeutics Holdings‘s full profile, request access.

Request a free trial

CERo Therapeutics Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cel
Drug Discovery
South San Francisco, CA
8 As of 2025

Emeryville, CA
 

Hummelstown, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CERo Therapeutics Holdings Competitors (4)

One of CERo Therapeutics Holdings’s 4 competitors is Eureka Therapeutics, a Venture Capital-Backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eureka Therapeutics Venture Capital-Backed Emeryville, CA
Bobcatbio Venture Capital-Backed Hummelstown, PA
PDS Biotechnology Formerly VC-backed Princeton, NJ
A2 Bio Venture Capital-Backed Agoura Hills, CA
To view CERo Therapeutics Holdings’s complete competitors history, request access »

CERo Therapeutics Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CERo Therapeutics Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CERo Therapeutics Holdings‘s full profile, request access.

Request a free trial

CERo Therapeutics Holdings Acquisitions (1)

CERo Therapeutics Holdings’s most recent deal was a Merger/Acquisition with Phoenix Biotech Acquisition for . The deal was made on 14-Feb-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Phoenix Biotech Acquisition 14-Feb-2024 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view CERo Therapeutics Holdings’s complete acquisitions history, request access »

CERo Therapeutics Holdings ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view CERo Therapeutics Holdings’s complete esg history, request access »

CERo Therapeutics Holdings Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
CERo Therapeutics South San Francisco, CA

CERo Therapeutics Holdings FAQs

  • When was CERo Therapeutics Holdings founded?

    CERo Therapeutics Holdings was founded in 2016.

  • Where is CERo Therapeutics Holdings headquartered?

    CERo Therapeutics Holdings is headquartered in South San Francisco, CA.

  • What is the size of CERo Therapeutics Holdings?

    CERo Therapeutics Holdings has 8 total employees.

  • What industry is CERo Therapeutics Holdings in?

    CERo Therapeutics Holdings’s primary industry is Drug Discovery.

  • Is CERo Therapeutics Holdings a private or public company?

    CERo Therapeutics Holdings is a Public company.

  • What is CERo Therapeutics Holdings’s stock symbol?

    The ticker symbol for CERo Therapeutics Holdings is CERO.

  • What is the current market cap of CERo Therapeutics Holdings?

    The current market capitalization of CERo Therapeutics Holdings is $344K.

  • Who are CERo Therapeutics Holdings’s competitors?

    Eureka Therapeutics, Bobcatbio, PDS Biotechnology, and A2 Bio are competitors of CERo Therapeutics Holdings.

  • What is CERo Therapeutics Holdings’s annual earnings per share (EPS)?

    CERo Therapeutics Holdings’s EPS for 12 months was $40.34.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process